<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="346">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 18, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04476953</url>
  </required_header>
  <id_info>
    <org_study_id>20-003936</org_study_id>
    <nct_id>NCT04476953</nct_id>
  </id_info>
  <brief_title>COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation</brief_title>
  <official_title>COVID-FISETIN: A Phase 2 Placebo-Controlled Pilot Study in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Hospitalized Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether Fisetin, a senolytic drug, can assist in&#xD;
      preventing an increase in the disease's progression and alleviate complications of&#xD;
      coronavirus due to an excessive inflammatory reaction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine if Fisetin treatment can prevent deterioration of oxygenation status as measured&#xD;
      by S/F ratio: SpO2/ FiO2, as well as prevent deterioration in physical function (frailty) and&#xD;
      hyper-inflammation, other measures of oxygenation status (progression to supplemental oxygen&#xD;
      requirement, assisted breathing/ ventilation), and progression from mild/ moderate to severe/&#xD;
      critical proven SARS-CoV-2 infection in hospitalized patients and to evaluate the safety and&#xD;
      tolerability of Fisetin in this patient population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 3, 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants to experience serious adverse events and hypersensitivity reactions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in oxygenation status</measure>
    <time_frame>baseline, Day 3, 7, 10, 14, 17 and 30; Months 3 and 6</time_frame>
    <description>change in oxygenation levels as measured by S/F ratio (SPO2/FiO2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CoV Severity Category</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants to progress to severe or critical classification CoV</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive treatment drug Fisetin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo looks exactly like the study drug, but it contains no active ingredient.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fisetin</intervention_name>
    <description>~20 mg/kg/day oral, NG or D tube course for 2 consecutive days</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>3,3',4',7-tetrahydroxyflavone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria - Patients must meet all of the following inclusion criteria to be&#xD;
        enrolled in this study.&#xD;
&#xD;
          1. Men or women 60 years of age or older&#xD;
&#xD;
             OR&#xD;
&#xD;
             Age 18 - 59 years WITH at least one of the following comorbidities:&#xD;
&#xD;
               -  BMI greater than or equal to 35&#xD;
&#xD;
               -  Diabetes&#xD;
&#xD;
               -  Asthma/ Chronic Obstructive Pulmonary Disease (COPD)&#xD;
&#xD;
               -  Previous Myocardial Infarction&#xD;
&#xD;
               -  Previous Stroke/ Cerebrovascular Accident (CVA)&#xD;
&#xD;
               -  Hypertension/ Atherosclerosis/ Peripheral Vascular Disease&#xD;
&#xD;
               -  Smoking and/or vaping&#xD;
&#xD;
               -  Other conditions associated with senescent cell accumulation (i.e. previous&#xD;
                  chemotherapy or radiation)&#xD;
&#xD;
          2. SpO2 greater than or equal to 85% (on room air or less than or equal to 2 L of&#xD;
             supplemental oxygen)&#xD;
&#xD;
          3. Willing and able to provide written informed consent or have a legally authorized&#xD;
             representative (LAR) who will provide informed consent&#xD;
&#xD;
          4. SARS-CoV-2 infection confirmed by PCR test at Mayo Clinic (or other CLIA certified)&#xD;
             laboratory within 10 days prior to randomization.&#xD;
&#xD;
        Exclusion Criteria - Patients who meet any of the following exclusion criteria are not to&#xD;
        be enrolled in this study.&#xD;
&#xD;
        General Exclusion Criteria&#xD;
&#xD;
          1. Presence of any condition that the Investigator or the subject's attending physician&#xD;
             believes would put the subject at risk or would preclude the patient from successfully&#xD;
             completing the trial&#xD;
&#xD;
          2. Pregnant and/or lactating. Women of childbearing potential (WCBP) must have a negative&#xD;
             pregnancy test within 72 hours prior to randomization&#xD;
&#xD;
          3. WCBP who are unwilling to abstain from sex or use an adequate method of contraception&#xD;
             from the time of the first IP administration through 48 hours after the last IP&#xD;
             administration&#xD;
&#xD;
          4. Men who are unwilling to abstain from sex with WCBP or use an adequate method of&#xD;
             contraception from the time of the first IP administration through 48 hours after the&#xD;
             last IP administration&#xD;
&#xD;
             Laboratory Exclusion Criteria&#xD;
&#xD;
          5. Total bilirubin &gt;3X upper limit of normal or as per clinical judgment.&#xD;
&#xD;
          6. Serum aspartate transaminase (AST) or alanine aminotransferase (ALT) &gt;4x the upper&#xD;
             limits of normal or as per clinical judgment.&#xD;
&#xD;
          7. Hemoglobin &lt;7 g/dL; white blood cell count ≤ 2,000/mm3 (&lt; or = 2.0 x 109/L) or &gt; or =&#xD;
             20,000/mm3 (&gt; or = 20 x 109/L); platelet count &lt; or = 40,000/µL (&lt; or = 40 x 109/L);&#xD;
             absolute neutrophil count &lt; or = 1 x 109/L; lymphocyte count &lt;0.3 x 109/L at screening&#xD;
             or as per clinical judgment.&#xD;
&#xD;
          8. Unstable (as per clinical judgment) major cardiovascular, renal, endocrine,&#xD;
             immunological, or hepatic disorder.&#xD;
&#xD;
          9. eGFR &lt;25 ml/ min/ 1.73 m2 or as per clinical judgment.&#xD;
&#xD;
         10. Plasma and/or serum glucose &gt;300 or as per clinical judgment.&#xD;
&#xD;
             Clinical History Exclusion Criteria&#xD;
&#xD;
         11. Human immunodeficiency virus infection.&#xD;
&#xD;
         12. Known active hepatitis B or C infection.&#xD;
&#xD;
         13. Invasive fungal infection.&#xD;
&#xD;
         14. Uncontrolled (as per clinical judgement) pleural/pericardial effusions or ascites.&#xD;
&#xD;
         15. New/active invasive cancer except non-melanoma skin cancers.&#xD;
&#xD;
             Medication Exclusion Criteria (See Appendices 1-3 for additional information)&#xD;
&#xD;
         16. Known hypersensitivity or allergy to Fisetin.&#xD;
&#xD;
         17. Patients currently using medications which utilize CYP450 2C9 for metabolism. These&#xD;
             medications include: Fosphenytoin, Phenytoin, Warfarin, Glimepiride, Diclofenac,&#xD;
             Bosentan, and Glyburide. Patients taking any of these medications may participate if&#xD;
             the medications can be held immediately before the 1st IP administration until at&#xD;
             least 10 hours after the last (2nd) IP administration and the patient is otherwise&#xD;
             eligible.&#xD;
&#xD;
         18. Patients currently using medications which utilize CYP2C9, CYP2C19, CYP1A2, OATP1B1.&#xD;
             These medications include: Olanzapine, Clozapine, Theophylline, Tizanidine, Warfarin,&#xD;
             Rameltoen, Tacrine, Duloxetine, Mexiletine, Riluzole, and Atomoxetine. Patients taking&#xD;
             any of these medications may participate if the medications can be held immediately&#xD;
             before the 1st IP administration until at least 10 hours after the last (2nd) IP&#xD;
             administration and the patient is otherwise eligible.&#xD;
&#xD;
         19. Patients currently using medications which are strong inhibitors of CYP3A4. These&#xD;
             medications include: Atazanavir, Ceritinib, Clarithromycin, Darunavir, Idelalisib,&#xD;
             Indinavir, Itraconazole, Ketoconazole, Lopinavir, Mefipristone, Nefazodone,&#xD;
             Nelfinavir, Ombitasivir-paritaprevir-ritonivir,&#xD;
             Ombitasivir-paritaprevir-ritonivir-plus dasabuvir, Posaconazole, Saquinavir,&#xD;
             Telithromycin, Tucatinib, and Voriconazole. Patients taking any of these medications&#xD;
             may participate if the medications can be held immediately before the 1st IP&#xD;
             administration until at least 10 hours after the last (2nd) IP administration and the&#xD;
             patient is otherwise eligible.&#xD;
&#xD;
         20. Patients currently using antifungals. If antifungals are absolutely necessary from an&#xD;
             infectious disease perspective, then they will be allowed only if the levels are&#xD;
             subtherapeutic or therapeutic.&#xD;
&#xD;
         21. Patients taking any of these medications may participate if the medications can be&#xD;
             held immediately before the 1st IP administration until at least 10 hours after the&#xD;
             last (2nd) IP administration and the patient is otherwise eligible:&#xD;
&#xD;
               -  Cardiac: digoxin, flecainide, amiodarone&#xD;
&#xD;
               -  Psychiatric: lithium, thioridazine&#xD;
&#xD;
               -  Neurologic: carbamazepine, phenobarbital&#xD;
&#xD;
               -  Antimicrobial/fungal: aminoglycosides (e.g. amikacin, gentamicin, kanamycin,&#xD;
                  neomycin, netilmicin, paromomysin, streptomycin, tobramycin), rifampin&#xD;
&#xD;
               -  Anticoagulants/ Antiplatelets: warfarin&#xD;
&#xD;
               -  Others: methotrexate, nitroglycerin, St. John's wort, tyrosine kinase inhibitors,&#xD;
                  tacrine, diclofenac&#xD;
&#xD;
         22. Participation in other clinical trials involving treatment for SARS-CoV-2. (unless&#xD;
             reviewed and approved by the Principal Investigator). Note that institutional standard&#xD;
             of care treatment of SARS-CoV-2 including glucocorticoids, hydroxychloroquine,&#xD;
             azithromycin, remdesivir, anti-spike antibodies, and/or convalescent plasma are not&#xD;
             excluded from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James L Kirkland</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 15, 2020</study_first_submitted>
  <study_first_submitted_qc>July 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2020</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>James L. Kirkland</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

